Apollomics, Inc. (NasdaqCM: APLM)
Health Care · Biotechnology · US
$23.40
+38.46% today · +310.5% 1Y
Apollomics, Inc. (NasdaqCM: APLM) operates in the Biotechnology industry within the Health Care sector. The company is valued at $51.39M and employs 14 people.
Over the last twelve months the share price has gained 310.5%, trading between 3.66 and 42.12.
Tweenvest scores Apollomics, Inc. across four factors: quality 22/100, value 72/100. Its strongest factor is value.
APLM price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $51.39M
- Revenue (TTM)
- $8.84M
- P/E
- —
- EPS
- -7.57
- Dividend yield
- —
- Beta (5Y)
- 1.45
- 52-week high
- $42.12
- 52-week low
- $3.66
- Avg volume (3M)
- —
- Shares outstanding
- 2.20M
- Employees
- 14
- Next earnings
- —
About Apollomics, Inc.
Apollomics, Inc., a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia. The company is dedicated to discovering and advancing innovative oncology treatments to address critical unmet medical requirements. Its therapeutic pipeline features APL-101 (Vebreltinib), a potent and selective c-Met inhibitor being developed for non-small cell lung cancer and other advanced malignancies. Also in development is APL-102, an orally administered, small molecule multiple tyrosine kinase inhibitor intended for liver, breast, and esophageal cancers. Furthermore, APL-122 is an investigational tumor inhibitor candidate focused on treating cancers within the brain. The organization was formerly known as CBT Pharmaceuticals, Inc. before adopting the name Apollomics, Inc. in January 2019.
- ISIN
- KYG0411D1236
- Founded
- 2015
- Listed since
- Nov 26, 2021
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $158.83 | +14.36% |
Figures last refreshed Aug 18, 2026.